Diabetic Neuropathy, Painful Clinical Trial
Official title:
Efficacy of Capacitive-Resistive Noninvasive Radiofrequency in Improving Perfusion Index and Attenuating Diabetic Neuropathic Pain; A Pre-post Study
Verified date | February 2024 |
Source | Cairo University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Peripheral neuropathy increases the prevalence of diabetic foot ulcers following a decrease in foot sensation. Therefore, the treatment of this disorder is very important.
Status | Completed |
Enrollment | 23 |
Est. completion date | January 30, 2024 |
Est. primary completion date | January 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 70 Years |
Eligibility | Inclusion Criteria: - Age 40-70 years - Type II DM with DPN (grade I-II) in lower limbs - Duration of DM>5 years - Visual Analog Scale (VAS) =3 in the feet - Sensory impairments in the lower extremities Exclusion Criteria: - Patient with previous stenting or surgical intervention of lower limb arterial system. - Patients with previous history of DVT. - Pregnancy - Diabetic infectious wound - Cardiac pacemaker presence - Severe liver and kidney dysfunction or history of heart and lung disease. |
Country | Name | City | State |
---|---|---|---|
Egypt | Medicine | Cairo |
Lead Sponsor | Collaborator |
---|---|
Cairo University |
Egypt,
Niajalili M, Sedaghat M, Reazasoltani A, Akbarzade Baghban AR, Sadat Naimi S. [Effect of Capacitive Tecar Therapy on Foot Pain and Tactile Sensation in Patients With Type 2 Diabetes (Persian)]. Archives of Rehabilitation. 2020; 21(3):304-319. https://doi.org/10.32598/RJ.21.3.60.5
Tashiro Y, Hasegawa S, Yokota Y, Nishiguchi S, Fukutani N, Shirooka H, Tasaka S, Matsushita T, Matsubara K, Nakayama Y, Sonoda T, Tsuboyama T, Aoyama T. Effect of Capacitive and Resistive electric transfer on haemoglobin saturation and tissue temperature. Int J Hyperthermia. 2017 Sep;33(6):696-702. doi: 10.1080/02656736.2017.1289252. Epub 2017 Feb 19. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change of the perfusion index at the end of the first session compared to baseline readings. | the perfusion index readings will be taken before the first session and set as baseline reading and after the first session and the change will be calculated.The Masimo SET "Mighty-Sat Fingertip Pulse Oximetry" (Masimo Corporation, Irvine, CA, USA model 9900) was attached to the big toe of each patient. the reading will be the the mean of three measurements of perfusion index (PI) taken at one-minute intervals. | 40 minutes | |
Secondary | Visual Analogue Scale | Patient defines the degree of pain on a visual scale without numeric values, while the values are visible on the back side for the registrar where 0 indicates no pain and 10 indicates the most unbearable pain. The test was performed before intervention, after each session and one month after the end of all twelve sessions. | 2 months | |
Secondary | Tactile sensation of the sole | Tactile sensation of the sole using Semmes-Weinstein monofilament 5.07/10 g. the test will be performed after each session. | 2 months | |
Secondary | Analgesic effect | Analgesic effect after each session; will be evaluated using the four grades of WHO evaluation criteria for pain relief:
Complete remission (CR) Partial remission (PR) Mild remission (MR) No response (NR). |
2 months | |
Secondary | The total remission rate | 2 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04988321 -
Theta Burst Brain Stimulation in Diabetic Neuropathy Patients With Neuropathic Pain: Investigating Neural Mechanisms
|
N/A | |
Completed |
NCT00385671 -
An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain
|
Phase 4 | |
Completed |
NCT00159679 -
Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy
|
Phase 4 | |
Completed |
NCT00141401 -
Safety and Efficacy of Pregabalin in Patients With Diabetic Peripheral Neuropathy.
|
Phase 3 | |
Active, not recruiting |
NCT04469270 -
Study to Assess Safety and Efficacy of Engensis in Painful Diabetic Peripheral Neuropathy
|
Phase 3 | |
Completed |
NCT00553475 -
Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy
|
Phase 3 | |
Completed |
NCT00381719 -
Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy
|
Phase 2 | |
Completed |
NCT00539175 -
Treatment of Painful Diabetic Neuropathy With Photon Stimulation
|
N/A | |
Completed |
NCT00058968 -
A Study for the Treatment of Painful Diabetic Neuropathy
|
Phase 3 | |
Completed |
NCT05029297 -
Study With Two Capsaicin Topic Treatments in Diabetic Neuropathy.
|
Phase 3 | |
Completed |
NCT02215252 -
A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN)
|
Phase 2 | |
Completed |
NCT00785577 -
A Study for Treatment of Pain in Patients With Diabetic Neuropathy.
|
Phase 2 | |
Completed |
NCT00858351 -
Thermal Biofeedback for the Treatment of Diabetic Neuropathy
|
N/A | |
Completed |
NCT03047278 -
Transporters for Organic Cations and Glycemic Control in Patients With Neuropathic Pain.
|
Phase 4 | |
Completed |
NCT01628627 -
Frequency Modulated Neural Stimulation (FREMS) in Symptomatic Diabetic Neuropathy
|
Phase 4 | |
Completed |
NCT03315598 -
Evaluation of an Effectiveness and Safety of the Electroacupuncture in the Management of Intractable Neuropathic Pain
|
N/A | |
Completed |
NCT01057693 -
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
|
Phase 3 | |
Completed |
NCT01564459 -
Study to Evaluate MK-6096 in the Treatment of Painful Diabetic Neuropathy (PDN) in Adults (MK-6096-021)
|
Phase 2 | |
Recruiting |
NCT01214590 -
Preliminary Assessment of the Efficacy of the VascuActiveâ„¢ Device on Diabetic Peripheral Neuropathy
|
N/A | |
Completed |
NCT01089556 -
A Study in Painful Diabetic Neuropathy
|
Phase 3 |